Research programme: retinitis pigmentosa therapeutics - Shire

Drug Profile

Research programme: retinitis pigmentosa therapeutics - Shire

Alternative Names: BIK-406; SHP-630

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator BIKAM Pharmaceuticals
  • Developer Foundation Fighting Blindness; Shire
  • Class Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Retinitis pigmentosa

Most Recent Events

  • 23 Oct 2015 Preclinical trials in Retinitis pigmentosa in USA (unspecified route)
  • 04 May 2015 Early research in Retinitis pigmentosa in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top